Application of Wireless Sensor Networks for Indoor Temperature Regulation

International audienceWireless sensor networks take a major part in our everyday lives by enhancing systems for home automation, healthcare, temperature control, energy consumption monitoring, and so forth. In this paper we focus on a system used for temperature regulation for residential, educational, industrial, and commercial premises, and so forth. We propose a framework for indoor temperature regulation and optimization using wireless sensor networks based on ZigBee platform. This paper considers architectural design of the system, as well as implementation guidelines. The proposed system favors methods that provide energy savings by reducing the amount of data transmissions through the network. Furthermore, the framework explores techniques for localization, such that the location of the nodes can be used by algorithms that regulate temperature settings

(E)-N-Benzyl­idene-4H-1,2,4-triazol-4-amine

The title compound, C9H8N4, crystallizes with three independent mol­ecules (A, B and C) per asymmetric unit. The independent mol­ecules differ slightly in their conformations, the dihedral angles between the triazole and phenyl rings in mol­ecules A, B and C being 4.8 (2), 9.7 (2) and 7.2 (2)°, respectively. In the crystal, the independent mol­ecules are linked into a trimer by C—H⋯N hydrogen bonds

Učinak eksrakta kore brucijskog bora (Pinus brutia) na čiste i mješovite kulture buražnih bakterija i arheja te na fermentacijske značajke buraga in vitro

The aim of the study was to investigate the effects of Pinus brutia bark extract, which is rich in polyphenolic compounds of tannins, on both pure and mixed continuous cultures of rumen bacteria and archaea, as well as on rumen fermentation characteristics in vitro. Antimicrobial susceptibility assay with pure cultures was carried out in an anaerobic chamber. Pinus brutia bark extract exhibited a potential inhibitor activity (P<0.05) against pure cultures of Ruminococcus flavefaciens, Eubacterium ruminantium, and Methanobacterium formicicum while a growth stimulatory effect (P<0.05) was observed for Ruminoccocus albus, Butyrivibrio fibrisolvens, and Streptococcus bovis. Pinus brutia bark extract only had a potential inhibitor effect (P<0.05) on R. albus at the highest dose (1200 μg/mL). Pinus brutia bark extract also stimulated (P<0.05) the growth of pure cultures of Fibrobacter succinogenes, while it did not affect Megasphaera elsdenii, except at the highest dose. The effects of two doses (75 and 375 mg/L) of P. brutia bark extract on in vitro mixed cultures and rumen fermentation parameters were determined by the rumen simulation technique (Rusitec). Supplementation with P. brutia bark extract led to a quadratic decrease (P<0.05) in the cell numbers of R. flavefaciens. Production of total and individual short chain fatty acids (SCFA), acetate to propionate ratio (C2/C3), total protozoa, ruminal pH, and dry matter digestibility (DMD) did not change in the presence of P. brutia bark extract. Supplementation with both doses of P. brutia bark extract decreased (P<0.05) the ammonia-N concentrations. Ammonia-N concentration was lowest in the high-supplemented group (P<0.05). As a conclusion, inhibitory effects of P. brutia bark extract on some species in the pure cultures were in the same direction as with mixed ruminal cultures, while stimulatory effects disappeared. The lack of inhibitory effects on protozoa and on a large number of Gram-positive rumen bacteria in the mixed cultures suggests that its mechanism of action is not exactly similar to antibiotics. Although P. brutia bark extract did not alter ruminal SCFA, it could have potential to improve ruminal protein utilization without depressing rumen microbial fermentation.Cilj ovog rada bio je istražiti učinak ekstrakta kore brucijskog bora (Pinus brutia), koji je bogat polifenolnim sastojcima tanina, na čiste i mješovite kulture buražnih bakterija i arheja kao i na in vitro fermentacijske značajke buraga. Proveden je test antimikrobne osjetljivosti s čistim kulturama u anaerobnim uvjetima. Ekstrakt kore brucijskog bora pokazao je potencijalnu inhibitornu aktivnost (P < 0,05) protiv čistih kultura bakterija Ruminococcus flavefaciens, Eubacterium ruminantium i Methanobacterium formicicum, a stimulacijski učinak na rast (P < 0,05) opažen je za bakterije Ruminoccocus albus, Butyrivibrio fibrisolvens i Streptococcus bovis. Ekstrakt kore brucijskog bora imao je potencijalan inhibitorni učinak (P < 0,05) na R. albus samo u najvećoj dozi (1200 μg/mL). Također je imao stimulacijski učinak (P < 0,05) na čiste kulture Fibrobacter succinogenes, a nije utjecao na Megasphaera elsdenii osim u najvećoj dozi. Učinak dviju doza (75 i 375 mg/L) ekstrakta kore brucijskog bora na in vitro mješovite culture i pokazatelje fermentacije u buragu određen je simulacijskom tehnikom (Rusitec). Dodatak ekstrakta kore brucijskog bora doveo je do kvadratnog smanjenja (P < 0,05) broja stanica R. flavefaciens. Nije bilo promjena u proizvodnji ukupnih i pojedinačnih kratkolančanih masnih kiselina (SCFA), omjeru acetata i propionata (C2/C3), ukupnom broju protozoa, buražnom pH i probavljivosti suhe tvari (DMD). Suplementacija objema dozama ekstrakta kore brucijskog bora smanjila je (P < 0,05) koncentracije amonijaka-N. Koncentracija amonijaka-N bila je najniža u skupini s najvećom dozom suplementa (P < 0,05). Zaključujemo da je inhibitorni učinak ekstrakta kore brucijskog bora na neke vrste u čistim kulturama bio jednak onomu u mješovitim buražnim kulturama, a nije bilo stimulacijskog efekta. Manjak inhibitornih učinaka na protozoe i na mnoge Gram-pozitivne buražne bakterije u mješovitim kulturama upućuje na to da njihov mehanizam djelovanja nije jednak onomu kod antibiotika. Premda ekstrakt kore brucijskog bora nije promijenio buražni SCFA, mogao bi poboljšati iskorištavanje proteina u buragu a da pritom ne suprimira mikrobnu fermentaciju

Accelerated diabetic wound healing by topical application of combination oral antidiabetic agents-loaded nanofibrous scaffolds: An in vitro and in vivo evaluation study

The combination of oral antidiabetic drugs, pioglitazone, metformin, and glibenclamide, which also exhibit the strongest anti-inflammatory action among oral antidiabetic drugs, were loaded into chitosan/gelatin/polycaprolactone (PCL) by electrospinning and polyvinyl pyrrolidone (PVP)/PCL composite nanofibrous scaffolds by pressurized gyration to compare the diabetic wound healing effect. The combination therapies significantly accelerated diabetic wound healing in type-1 diabetic rats and organized densely packed collagen fibers in the dermis, it also showed better regeneration of the dermis and epidermis than single drug-loaded scaffolds with less inflammatory cell infiltration and edema. The formation of the hair follicles started in 14 days only in the combination therapy and lower proinflammatory cytokine levels were observed compared to single drug-loaded treatment groups. The combination therapy increased the wettability and hydrophilicity of scaffolds, demonstrated sustained drug release over 14 days, has high tensile strength and suitable cytocompatibility on L929 (mouse fibroblast) cell and created a suitable area for the proliferation of fibroblast cells. Consequently, the application of metformin and pioglitazone-loaded chitosan/gelatin/PCL nanofibrous scaffolds to a diabetic wound area offer high bioavailability, fewer systemic side effects, and reduced frequency of dosage and amount of drug

Natural coagulates for wastewater treatment; a review for application and mechanism

The increase of water demand and wastewater generation is among the global concerns in the world. The less effective management of water sources leads to serious consequences, the direct disposal of untreated wastewater is associated with the environmental pollution, elimination of aquatic life and the spread of deadly epidemics. The flocculation process is one of the most important stages in water and wastewater treatment plants, wherein this phase the plankton, colloidal particles, and pollutants are precipitated and removed. Two major types of coagulants are used in the flocculation process included the chemical and natural coagulants. Many studies have been performed to optimize the flocculation process while most of these studies have confirmed the hazardous effects of chemical coagulants utilization on the ecosystem. This chapter reviews a summary of the coagulation/flocculation processes using natural coagulants as well as reviews one of the most effective natural methods of water and wastewater treatment

Galactose epimerase deficiency: lessons from the GalNet registry.

BACKGROUND Galactose epimerase (GALE) deficiency is a rare hereditary disorder of galactose metabolism with only a few cases described in the literature. This study aims to present the data of patients with GALE deficiency from different countries included through the Galactosemia Network to further expand the existing knowledge and review the current diagnostic strategy, treatment and follow-up of this not well characterized entity. METHODS Observational study collecting medical data from December 2014 to April 2022 of 22 not previously reported patients from 14 centers in 9 countries. Patients were classified as generalized or non-generalized based on their genotype, enzyme activities in different tissues and/or clinical picture and professional judgment of the treating physician. RESULTS In total 6 patients were classified as generalized and 16 as non-generalized. In the generalized group, acute neonatal illness was reported in 3, cognitive and developmental delays were present in 5 and hearing problems were reported in 3. Four generalized patients were homozygous for the genetic variant NM_001008216.2:c.280G > A (p.Val94Met). In the non-generalized group, no clearly related symptoms were found. Ten novel genetic variants were reported in this study population. CONCLUSION The phenotypic spectrum of GALE deficiency ranges from asymptomatic to severe. The generalized patients have a phenotype that is in line with the 9 described cases in the literature and prescribing dietary interventions is the cornerstone for treatment. In the non-generalized group, treatment advice is more difficult. To be able to offer proper counseling, in addition to red blood cell enzyme activity, genetic studies, transferrin glycoform analysis and enzymatic measurements in fibroblasts are recommended. Due to lack of facilities, additional enzymatic testing is not common practice in many centers nor a tailored long-term follow-up is performed

A Multinational Study of Acute and Long‐Term Outcomes of Type 1 Galactosemia Patients Who Carry the S135L (c.404C > T) Variant of GALT

Patients with galactosemia who carry the S135L (c.404C > T) variant of galactose-1-P uridylyltransferase (GALT), documented to encode low-level residual GALT activity, have been under-represented in most prior studies of outcomes in Type 1 galactosemia. What is known about the acute and long-term outcomes of these patients, therefore, is based on very limited data. Here, we present a study comparing acute and long-term outcomes of 12 patients homozygous for S135L, 25 patients compound heterozygous for S135L, and 105 patients homozygous for two GALT-null (G) alleles. This is the largest cohort of S135L patients characterized to date. Acute disease following milk exposure in the newborn period was common among patients in all 3 comparison groups in our study, as were long-term complications in the domains of speech, cognition, and motor outcomes. In contrast, while at least 80% of both GALT-null and S135L compound heterozygous girls and women showed evidence of an adverse ovarian outcome, prevalence was only 25% among S135L homozygotes. Further, all young women in this study with even one copy of S135L achieved spontaneous menarche; this is true for only about 33% of women with classic galactosemia. Overall, we observed that while most long-term outcomes trended milder among groups of patients with even one copy of S135L, many individual patients, either homozygous or compound heterozygous for S135L, nonetheless experienced long-term outcomes that were not mild. This was true despite detection by newborn screening and both early and life-long dietary restriction of galactose. This information should empower more evidence-based counseling for galactosemia patients with S135L.info:eu-repo/semantics/publishedVersio